The publication in a peer-reviewed journal and encouraging OS data (17.3 months in refractory HNSCC) could drive near-term speculative buying. However, the stock has historically reversed gains within 5 days on similar news. Monitor for partnership announcements or financing updates; the SYN-004 trial is stalled pending funding, which may cap upside.
Price Chart
Executive Summary
Theriva Biologics announced publication of Phase 1 trial results for VCN-01 in immunotherapy-refractory HNSCC in Clinical Cancer Research. The data showed median overall survival of up to 17.3 months in the high-dose sequential arm, with translational evidence of immune resensitization. This is a positive clinical validation for a micro-cap biotech with no approved products, but the trial was small (20 patients) and the stock has historically been highly volatile with negative T+5 returns on prior positive news.
Key Facts
- Phase 1 trial results published in Clinical Cancer Research for VCN-01 + durvalumab in immunotherapy-refractory metastatic HNSCC
- Median overall survival: 10.3 months (Arm I LD), 15.5 months (Arm II LD), 17.3 months (Arm II HD)
- Median progression-free survival: 1.6 months (Arm I LD), 3.7 months (Arm II LD), 2.1 months (Arm II HD)
- Biomarker data showed increased PD-L1+ T-cells, CD8 upregulation, and reduced Treg markers consistent with immune reactivation
- 20 patients enrolled across three arms; no new safety signals highlighted
- SYN-004 (ribaxamase) HCT trial has completed 2 of 3 cohorts, with third cohort dependent on additional funding
Financial Impact
No financial data provided; pre-revenue clinical-stage company with $11M market cap. Positive Phase 1 data may support partnering or financing but no near-term revenue.
Risk Factors
- Micro-cap biotech with $11M market cap — high volatility and liquidity risk
- Phase 1 data is early; larger randomized trials needed for regulatory approval
- SYN-004 HCT trial requires additional funding to complete third cohort
- Historical T+5 returns on prior positive news were negative (-14.6% on April 17 report)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310376 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $0.2300 $0.2490 | ▲ +8.26% | ▲ +9.32% | $0.2306 (+0.26%) |
Aug 11, 2026 7w ago | Press Release | $0.2300 $0.2490 | ▲ +8.26% | ▲ +9.32% | $0.2306 (+0.26%) |
Aug 4, 2026 8w ago | 8-K | $0.2300 $0.2490 | ▼ −8.26% | ▼ −9.50% | $0.2306 (−0.26%) |
Jul 7, 2026 12w ago | 8-K | $0.2354 $0.2227 | ▼ −5.40% | ▼ −6.73% | $0.2306 (−2.04%) |
Jun 11, 2026 16w ago | Press Release | $0.3070 $0.2345 | ▼ −23.62% | ▼ −25.51% | $0.2306 (−24.89%) |
Apr 17, 2026 23w ago | 8-K | $0.4100 $0.3000 | ▼ −26.83% | ▼ −31.03% | $0.2306 (−43.76%) |
Mar 12, 2026 29w ago | 8-K | $0.1800 $0.2300 | ▲ +27.78% | ▲ +25.80% | $0.2306 (+28.11%) |
Mar 12, 2026 29w ago | Press Release | $0.1800 $0.2300 | ▲ +27.78% | ▲ +25.80% | $0.2306 (+28.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access